StockNews.com Upgrades Regulus Therapeutics (NASDAQ:RGLS) to “Sell”

Regulus Therapeutics (NASDAQ:RGLS) was upgraded by research analysts at StockNews.com to a “sell” rating in a report released on Tuesday.

Several other equities research analysts have also commented on the company. Oppenheimer reissued an “outperform” rating and set a $7.00 price target on shares of Regulus Therapeutics in a research note on Wednesday, August 14th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Regulus Therapeutics in a research report on Friday, August 9th. Finally, Canaccord Genuity Group lifted their price objective on Regulus Therapeutics from $11.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Regulus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.80.

Regulus Therapeutics Price Performance

Shares of NASDAQ:RGLS opened at $1.58 on Tuesday. The business’s 50 day simple moving average is $1.65 and its 200-day simple moving average is $2.04. The firm has a market capitalization of $103.44 million, a price-to-earnings ratio of -1.08 and a beta of 1.63. Regulus Therapeutics has a 12 month low of $1.08 and a 12 month high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.17) EPS for the quarter, hitting the consensus estimate of ($0.17). On average, equities analysts anticipate that Regulus Therapeutics will post -0.8 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of RGLS. Victory Capital Management Inc. raised its holdings in Regulus Therapeutics by 16.5% in the 4th quarter. Victory Capital Management Inc. now owns 271,736 shares of the biopharmaceutical company’s stock valued at $348,000 after acquiring an additional 38,529 shares during the last quarter. CVI Holdings LLC acquired a new position in Regulus Therapeutics in the 1st quarter valued at $4,050,000. Vanguard Group Inc. raised its holdings in Regulus Therapeutics by 158.4% in the 1st quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock valued at $2,132,000 after acquiring an additional 453,784 shares during the last quarter. NEA Management Company LLC acquired a new position in Regulus Therapeutics in the 1st quarter valued at $18,627,000. Finally, RA Capital Management L.P. acquired a new position in Regulus Therapeutics in the 1st quarter valued at $18,000,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.